Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 15 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

2 trials in Phase 3/4

Results Transparency

22%

2 of 9 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

7(53.8%)

Phase 2

4(30.8%)

Phase 3

2(15.4%)

13Total

Phase 1(7)

Phase 2(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT07540364Phase 3Not Yet Recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy

Role: lead

NCT06126497Phase 2Completed

Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

Role: lead

NCT05397639Phase 3Recruiting

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Role: lead

NCT06836063Phase 2Active Not Recruiting

Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

Role: lead

NCT06705088Phase 1Recruiting

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SUVN-I6107 In Healthy Participants

Role: lead

NCT04072380Phase 2Completed

A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

Role: lead

NCT02580305Phase 2Completed

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

Role: lead

NCT05530447Unknown

Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy

Role: lead

NCT03564964Unknown

Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease

Role: lead

NCT03551288Phase 1Completed

Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects

Role: lead

NCT03155503Phase 1Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects

Role: lead

NCT03031574Phase 1Completed

A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-D4010 in Healthy Subjects

Role: lead

NCT02881294Phase 1Completed

A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-G3031 in Healthy Subjects

Role: lead

NCT02342041Phase 1Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects

Role: lead

NCT02575482Phase 1Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects

Role: lead

All 15 trials loaded